Sr. Research Associate I/II, Gene Editing

Scribe Therapeutics is a molecular engineering company focused on creating best-in-class in vivo therapies that permanently treat the underlying cause of disease. Founded by CRISPR inventors and leading molecular engineers Benjamin Oakes, Brett Staahl, David Savage, and Jennifer Doudna, Scribe is overcoming the limitations of current genome editing technologies by developing custom engineered enzymes and delivery modalities as part of a proprietary, evergreen CRISPR by Design™ platform for CRISPR-based genetic medicine.

 

We are seeking a highly creative, passionate, and motivated individual to join us in our quest to develop the next generation of CRISPR-based therapeutics. The current role is for a Research Associate to advance our ongoing efforts to engineer highly active and specific CRISPR enzymes. The candidate should have a passion for characterizing the CRISPR systems that advance our therapeutic programs. The role will work collaboratively across interdisciplinary teams, including protein engineers, process sciences, computational biologists, NGS, and disease experts. The candidate should bring experience in molecular biology and cell culture, and a passion for creating tools to meet the challenge of this new frontier in genetic medicine. 

 

The candidate will have numerous opportunities for professional growth in a rapidly growing biotechnology start-up, which includes growing into a role of increasing responsibilities and the ability to publish highly impactful work in peer reviewed journals. 

 

Key Responsibilities:

• Develop, optimize and validate molecular and cell-based assays. 
• Execute in vitro cellular and molecular biology assays, analyze and document results.
• Communicate research plans and results to team members verbally and in writing.
• Effectively collaborate with members within a fully integrated team to facilitate execution on projects within established timelines.
• Foster a driven, fast-paced, dynamic, and fun environment in which to do rigorous science.

 

Required Skills and Background:

• A Bachelor’s and/or Masters in Biology, Bioengineering, Cell biology, Genetics, or related discipline with  3+ years (Msc) or 5+ years experience (Bsc) relevant experience 
• Hands-on experience analyzing DNA/RNAs methods or proteins (ELISA, qPCR, ddPCR, flow cytometry, western blot, and other techniques). Method development experience  with qPCR and/or ddPCR  is highly valued.
• Proficient in molecular biology techniques common in upstream research, including molecular cloning, lentivirus production and titering, processing genomic DNA and RNA for downstream analysis
• Experience culturing common mammalian cell lines
• Ability to work both independently and collaboratively in a fast-paced, interdisciplinary research team.

 

Preferred Skills and Background:

• Experience with CRISPR-Cas gene editing systems and delivery technology. 
• Experience with high throughput or high content assays.
• Experience with material processing and library generation for NGS based assays      
• Previous Pharma, Biotech or CRO experience.

Salary will be commensurate with experience. We will provide an intellectually stimulating, collegial and fast-paced environment. If you are ready to engineer the future of therapeutics, then we are excited to hear from you! Visit us at www.scribetx.com.  

We are committed to creating a diverse environment and are proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.

At the time of posting, the base pay wage range for this role is $85,000-$130,000 per year.  The offered pay range will depend on internal equity and the candidate’s relevant skills, experience, qualifications, training, and market data.  Additional incentives are provided as part of the complete package in addition to comprehensive medical and other benefits.